Paul Workman

The European School of Oncology came into existence to respond to a need for information, education and training in the field of the diagnosis and treatment of cancer. There are two main reasons why such an initiative was considered necessary. Firstly, the teaching of oncology requires a rigorously multidisciplinary approach which is difficult for the Universities to put into practice since their system is mainly disciplinary orientated. Secondly, the rate of technological development that impinges on the diagnosis and treatment of cancer has been so rapid that it is not an easy task for medical faculties to adapt their curricula flexibly. With its residential courses for organ pathologies and the seminars on new techniques (laser, monoclonal antibodies, imaging techniques etc.) or on the principal therapeutic controversies (conservative or mutilating surgery, primary or adjuvant chemotherapy, radiotherapy alone or integrated), it is the ambition of the European School of Oncology to fill a cultural and scientific gap and, thereby, create a bridge between the University and Industry and between these two and daily medical practice. One of the more recent initiatives of ESO has been the institution of permanent study groups, also called task forces, where a limited number of leading experts are invited to meet once a year with the aim of defining the state of the art and possibly reaching a consensus on future developments in specific fields of oncology.

Vol. II

New Approaches in Cancer Pharmacology: Drug Design and Development

David J. Kerr

This book covers a wide range of novel biochemical targets that appear to be the best leads in terms of designing novel targets for anticancer drug design. New Molecular Targets for Cancer Chemotherapy is a unique, multi-disciplinary effort, with internationally respected authors from the fields of growth factor-receptor interaction, phosphoinositide and phospholipase signal transduction, and DNA-drug binding interactions. The science is placed in clinical context and illustrations explain how clinicians can incorporate a mechanistic, pharmacodynamic approach into early clinical trial design.

Paul Workman

Books

Your next favorite book is out there